Abstract
Genospace, a provider of cloud-based precision medicine software tools, announced a merger agreement under which it will become a wholly owned subsidairy of Sarah Cannon, the global cancer institute of Hospital Corporation of America (HCA). According to Sarah Cannon, the Genospace technology will allow it to use molecular profiling data to more effectively match cancer patients to clinical trials.
“Genospace’s innovative technology approach to understanding each patient’s cancer directly supports our strategic goal of personalizing care delivery,” said Jonathan B. Perlin, M.D., Ph.D., president, clinical services, and chief medical officer at HCA. “By tailoring treatments based on the unique genetic make-up of a patient’s cancer, we can more effectively treat the disease.”
Genospace will retain its Cambridge, MA headquarters, and lead development of a cloud-based system to allow the analysis of disparate data from clinical and laboratory sources across patient populations.